Hims & Hers Health gains as investors appear to lean into growth outlook and global expansion

Hims & Hers Health (HIMS) is up 6.7% today. Here is some analysis on what might have caused this price movement.

Analysis: There does not appear to be a single fresh company announcement driving the move today, so the rally likely reflects continued investor optimism around Hims & Hers’ growth story. This could be because the market is still digesting the company’s raised 2026 outlook, expanding weight-loss offering mix, and recently completed Eucalyptus acquisition, with an added boost from a recent insider purchase.

Details:

In first-quarter 2026 results, Hims & Hers posted about $608.1 million in revenue, said subscribers reached nearly 2.6 million, and raised full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion.

Management said its domestic business was accelerating and that a strategic pivot into a broader assortment of branded GLP-1 products was producing encouraging early demand signals.

On June 2, the company completed its acquisition of Eucalyptus, expanding its footprint across multiple international markets and adding a business that had served more than 850,000 customers.

A recent SEC Form 4 showed director David B. Wells bought 48,400 shares on May 26 at about $24.24 each, an open-market purchase that may have reinforced bullish sentiment.

Sources:

Hims & Hers, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HIMS Insider Trading Activity

$HIMS insiders have traded $HIMS stock on the open market 20 times in the past 6 months. Of those trades, 1 have been purchases and 19 have been sales.

Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:

OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 142,203 shares for an estimated $4,077,695.
MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,316 shares for an estimated $2,843,915.
DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
MOHAMED ELSHENAWY (CTO) sold 30,040 shares for an estimated $946,260
IRENE BECKLUND (PAO) has made 0 purchases and 3 sales selling 17,592 shares for an estimated $507,029.
SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 3 sales selling 18,926 shares for an estimated $473,439.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$HIMS Hedge Fund Activity

We have seen 230 institutional investors add shares of $HIMS stock to their portfolio, and 369 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL WORLD INVESTORS removed 14,322,912 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $297,343,653
FORERUNNER VENTURES MANAGEMENT, LLC removed 9,756,893 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $316,806,315
GOLDMAN SACHS GROUP INC removed 7,892,648 shares (-76.3%) from their portfolio in Q1 2026, for an estimated $163,851,372
DEFIANCE ETFS, LLC added 7,424,258 shares (+inf%) to their portfolio in Q1 2026, for an estimated $154,127,596
MORGAN STANLEY added 4,959,856 shares (+126.2%) to their portfolio in Q1 2026, for an estimated $102,966,610
FARALLON CAPITAL MANAGEMENT LLC removed 3,376,986 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $70,106,229
BANK OF AMERICA CORP /DE/ added 2,877,550 shares (+194.4%) to their portfolio in Q1 2026, for an estimated $59,737,938

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HIMS Price Targets

Multiple analysts have issued price targets for $HIMS recently. We have seen 12 analysts offer price targets for $HIMS in the last 6 months, with a median target of $26.5.

Here are some recent targets:

Allen Lutz from B of A Securities set a target price of $25.0 on 05/26/2026
Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026
Ryan MacDonald from Needham set a target price of $35.0 on 05/12/2026
Cory Carpenter from JP Morgan set a target price of $33.0 on 05/12/2026
Daniel Grosslight from Citigroup set a target price of $28.0 on 05/12/2026
Jonna Kim from TD Cowen set a target price of $23.0 on 03/27/2026
Michael Cherny from Leerink Partners set a target price of $25.0 on 03/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.